APEPTICO, a privately-held biotechnology company developing peptide drugs based on its PEPBASE? discovery technology, today announced the initiation of a Phase I clinical trial with its lead product AP301 to assess the safety and tolerability of the orally inhaled peptide drug. AP301 is being developed for the treatment of oedematous respiratory failure in patients suffering from lung infection, lung injury and lung transplantation...
No comments:
Post a Comment